Navigation Links
Sanford-Burnham researchers find molecular switch that allows melanoma to resist therapy
Date:2/2/2012

LA JOLLA, Calif. -- The National Cancer Institute (NCI) estimates that as many as one in 51 men and women will be diagnosed with melanomathe deadliest form of skin cancerat some point during their lifetimes. A research team led by Ze'ev Ronai, Ph.D. at Sanford-Burnham Medical Research Institute (Sanford-Burnham) is working to unravel the molecular mechanisms underlying the development and progression of this disease in hopes of improving prevention and treatment strategies. To do this, Ronai's laboratory has been studying a protein named Activating Transcription Factor 2 (ATF2), which is associated with poor prognosis in melanoma. ATF2 is a two-faced proteinin melanoma cells, it's oncogenic, or cancer-causing, while in non-malignant types of skin cancers, it acts as a tumor suppressor. In a paper published February 3 in the journal Cell, the team identified a molecular switch that controls ATF2's dual functions. This switch is controlled by protein kinase Cε (PKCε), which disables ATF2's tumor-suppressing activities, sensitizing cells to chemotherapy; instead, ATF2's tumor-promoting activity is enhanced. The team also found that high levels of PKCε in melanoma are associated with poor prognosis.

"PKCε is the culprit behind melanoma's 'oncogenic addiction,'" said Ronai, associate director of the Sanford-Burnham's NCI-designated Cancer Center and senior author of the study. "ATF2 is normally a 'good guy.' But when there is too much PKCεas in malignant melanomaATF2 becomes an oncogene, promoting tumor development."

In this study, Ronai and lead author Eric Lau, Ph.D., a postdoctoral researcher in his lab, found that PKCε's malignant power is in its ability to direct ATF2's location and activity within a cell. In a normal cell, PKCε modifies ATF2, keeping it in the nucleus, where it turns genes on and off and helps repair damaged DNA. When the cell experiences exposure to toxicity or stress (radiation, for example), PKCε backs off and ATF2 is able to move out of the nucleus and to the mitochondria, the part of the cell that generates energy and helps control cellular life and death. When it gets there, ATF2 helps to set the cell on a death coursea safeguard cells use to prevent errors that often make them cancerous.

PKCε levels are abnormally high in melanoma, and more PKCε means more ATF2 stuck in the nucleus, where it can't help the cells to die. Instead, in the nucleus, ATF2 promotes cellular survival and thus contributes to tumor development.

"We found that melanoma patients with high PKCε levels in their primary tumors were more likely to experience shorter survival times," said Lau. "This finding is consistent with earlier analyses of human melanoma tumors that showed a similar correlation between increased nuclear ATF2 and poor clinical outcome."

The Ronai laboratory, in collaboration with Sanford-Burnham's Conrad Prebys Center for Chemical Genomics, is currently searching for small molecules that help release ATF2 from PKCε's grip, thereby resuming ATF2's ability to promote cell death when needed. Since such an approach will effectively kill melanoma cells, it is expected to offer new therapeutic options for melanoma, and possibly other tumors with high PKCε levels.

"This work has clear potential for translation from a basic laboratory discovery to a melanoma therapy," said Michael Jackson, Ph.D., vice president of drug discovery and development at Sanford-Burnham. "We are excited to begin the screening process to identify a new class of drugs to treat cancer."


'/>"/>
Contact: Heather Buschman, Ph.D.
hbuschman@sanfordburnham.org
858-795-5343
Sanford-Burnham Medical Research Institute
Source:Eurekalert  

Related medicine news :

1. Scripps Health and Sanford-Burnham to collaborate to advance new cancer treatments
2. Dr. Kristiina Vuori Promoted to President of Sanford-Burnham Medical Research Institute
3. Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche
4. Researchers Spot Potential Bile Duct Cancer Drug Targets
5. Georgetown Lombardi researchers present new findings on head & neck cancers
6. Researchers discover method to unravel malarias genetic secrets
7. Researchers quantify muscle soreness
8. Georgetown professor applauds decision of researchers to temporarily halt research on H5N1
9. Health benefits of exercise may depend on cellular degradation, UT Southwestern researchers report
10. Autism redefined: Yale researchers study impact of proposed diagnostic criteria
11. University of Tennessee researchers develop comprehensive, accessible vision testing device
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sanford-Burnham researchers find molecular switch that allows melanoma to resist therapy
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... 2016 , , , WHEN: ... 2016 , , , , LOCATION: , , , Online, ... , , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global ... Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager ... pharmaceutical industry is witnessing an exceptional era. Several new demand spaces, ...
(Date:6/23/2016)... , June 23, 2016 The vast ... an outpatient dialysis facility.  Treatments are usually 3 times ... hours per visit, including travel time, equipment preparation and ... patient, but especially grueling for patients who are elderly ... a skilled nursing and rehabilitation centers for some duration ...
Breaking Medicine Technology: